1. Home
  2. GNFT vs NYXH Comparison

GNFT vs NYXH Comparison

Compare GNFT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNFT
  • NYXH
  • Stock Information
  • Founded
  • GNFT 1999
  • NYXH 2009
  • Country
  • GNFT France
  • NYXH Belgium
  • Employees
  • GNFT N/A
  • NYXH N/A
  • Industry
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • NYXH Medical/Dental Instruments
  • Sector
  • GNFT Health Care
  • NYXH Health Care
  • Exchange
  • GNFT Nasdaq
  • NYXH Nasdaq
  • Market Cap
  • GNFT 214.5M
  • NYXH 222.3M
  • IPO Year
  • GNFT 2019
  • NYXH 2021
  • Fundamental
  • Price
  • GNFT N/A
  • NYXH $7.77
  • Analyst Decision
  • GNFT Strong Buy
  • NYXH Strong Buy
  • Analyst Count
  • GNFT 1
  • NYXH 4
  • Target Price
  • GNFT $13.00
  • NYXH $14.50
  • AVG Volume (30 Days)
  • GNFT 4.2K
  • NYXH 41.5K
  • Earning Date
  • GNFT 04-24-2025
  • NYXH 08-05-2025
  • Dividend Yield
  • GNFT N/A
  • NYXH N/A
  • EPS Growth
  • GNFT N/A
  • NYXH N/A
  • EPS
  • GNFT 0.03
  • NYXH N/A
  • Revenue
  • GNFT $73,187,701.00
  • NYXH $4,716,818.00
  • Revenue This Year
  • GNFT $15.98
  • NYXH $323.07
  • Revenue Next Year
  • GNFT N/A
  • NYXH $204.30
  • P/E Ratio
  • GNFT $125.30
  • NYXH N/A
  • Revenue Growth
  • GNFT 105.01
  • NYXH N/A
  • 52 Week Low
  • GNFT $2.55
  • NYXH $5.55
  • 52 Week High
  • GNFT $6.42
  • NYXH $11.87
  • Technical
  • Relative Strength Index (RSI)
  • GNFT 47.81
  • NYXH 56.92
  • Support Level
  • GNFT $3.61
  • NYXH $7.30
  • Resistance Level
  • GNFT $3.95
  • NYXH $8.02
  • Average True Range (ATR)
  • GNFT 0.14
  • NYXH 0.26
  • MACD
  • GNFT -0.01
  • NYXH -0.04
  • Stochastic Oscillator
  • GNFT 57.01
  • NYXH 65.28

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: